Sector News

Stryker acquires SafeWire product portfolio

April 12, 2016
Life sciences

Stryker’s Spine division today announced the acquisition of the SafeWire product portfolio, including the Y-Wire guidewire and Tiger Jamshidi Needle Family for use in minimally invasive spine surgery.

The acquisition is highly complementary to Stryker’s current spine product portfolio and is aligned with the Spine division’s strategy of expanding its product offering for minimally-invasive spine surgery.

Acquired from SafeWire, the Y-Wire features a patented feature that is designed to mitigate potential wire-based complications, such as inadvertent advancement of the guidewire through bone, accidental pullout, kinking, or wire migration. In addition, with reduced surgical steps and technical ease, the Y-Wire helps to optimize workflow for minimally invasive spine cases, and to significantly reduce patient and surgeon exposure to fluoroscopy.1

Brad Paddock, president of Stryker’s Spine division, said the introduction of the SafeWire portfolio reflects Stryker’s ongoing commitment to patient safety and to providing surgeons with innovative technology needed to treat patients undergoing minimally-invasive spine surgery. “We are excited to bring this important complementary technology into the Stryker family,” Paddock said. “This acquisition increases our competitive advantage as we broaden our product line and extend our customer base among teaching facilities, competitive accounts, and existing SafeWire customers.”

Source: Stryker

comments closed

Related News

September 25, 2022

Teva CEO Schultz likely won’t renew employment contract next year: reports

Life sciences

Over the weekend, Teva revealed plans to finalize its $4.35 billion national opioid settlement by the end of the year and start paying up in 2023, possibly under the helm of a new CEO as Kåre Schultz added he will not renew his CEO contract come November 2023.

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.